Abstract: In the operation of analytical devices, and particularly laser induced breakdown spectroscopy (LIBS) devices, a number of advantages may be obtained by the use of complementary safety mechanisms, such as those that govern the operation or firing of a laser. Such complementary safety mechanisms, compared to the individual safety mechanisms acting alone, prevent operation of the laser under a greater number of unsafe circumstances (even if one or more detected conditions are safe, based on not activating the associated safety mechanism) and permits operation under a greater number of safe circumstances (even if one or more detected conditions are unsafe, based on activating the associated safety mechanism).

Abstract: In the operation of analytical devices, and particularly laser induced breakdown spectroscopy (LIBS) devices, a number of advantages may be obtained by the use of complementary safety mechanisms, such as those that govern the operation or firing of a laser. Such complementary safety mechanisms, compared to the individual safety mechanisms acting alone, prevent operation of the laser under a greater number of unsafe circumstances (even if one or more detected conditions are safe, based on not activating the associated safety mechanism) and permits operation under a greater number of safe circumstances (even if one or more detected conditions are unsafe, based on activating the associated safety mechanism).

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

Abstract: One aspect of the invention relates to a method (10) for characterizing a well (700) using distributed temperature sensor (DTS) data to optimise a well model (12). The method comprises providing a well model of flow and thermal properties (12a, 12b) of the well (700), where the well model (12) has a plurality of adjustable physical parameters, providing a data set made up of a plurality of DTS temperature profiles of the well (700) taken at different times during operation of the well (700), and running the well model (12) with different combinations of the plurality of adjustable physical parameters to match to the plurality of DTS temperature profiles. The DTS temperature profiles may also be pre-processed to make them consistent with one another.

Abstract: The present invention provides a shelf-stable mousse comprising an aerated oil-in-water emulsion characterised in that the mousse has a storage modulus at 20° C. of less than 50,000 Pa. It also provides a process to prepare said mousse.

Abstract: One aspect of the invention relates to a method (10) for characterising a well (700) using distributed temperature sensor (DTS) data to optimise a well model (12). The method comprises providing a well model of flow and thermal properties (12a, 12b) of the well (700), where the well model (12) has a plurality of adjustable physical parameters, providing a data set made up of a plurality of DTS temperature profiles of the well (700) taken at different times during operation of the well (700), and running the well model (12) with different combinations of the plurality of adjustable physical parameters to match to the plurality of DTS temperature profiles. The DTS temperature profiles may also be pre-processed to make them consistent with one another.

Abstract: A medicinal or cosmetic composition comprising Aloe vera in combination with at least one vitamin, a minerals concentrate, an organic oils concentrate, at least one Chinese Herb, at least one essential oil and at least one spice. The composition may be administered orally or topically.

Abstract: A medicinal or cosmetic composition comprising Aloe vera in combination with at least one vitamin, a minerals concentrate, an organic oils concentrate, at least one Chinese Herb, at least one essential oil and at least one spice. The composition may be administered orally or topically.

Abstract: A clamp, clamping means incorporating the clamp, and a method of clamping are disclosed. The clamp includes means for clamping a securing tie therein, together with means for attachment to a surface, and, in combination with a securing tie, provides a clamping means suitable for clamping objects to a fixed point.